Navigation Links
Analysis of Longer-Term Clinical Study Suggests Psychiatric Hospitalization Rates Decreased in Adults with Schizophrenia Treated With INVEGA® SUSTENNA®
Date:11/19/2010

ORLANDO, Fla., Nov. 19, 2010 /PRNewswire/ -- Schizophrenia is a chronic and disabling brain disorder that affects 1 percent of the U.S. population and results in substantial medical and societal costs, in particular from use of health-care resources. It also can have devastating health-related and social effects on people with the disease, their families and caregivers.

A pre-specified analysis from a longer-term clinical study presented at the U.S. Psychiatric and Mental Health Congress today suggests that psychiatric hospitalization rates decreased for adults with schizophrenia who were treated with INVEGA® SUSTENNA® (paliperidone palmitate), a long-acting atypical antipsychotic for acute and maintenance treatment of schizophrenia in adults.

"This study suggests that INVEGA SUSTENNA may have potential to reduce psychiatric hospitalization rates," said Chris M. Kozma, PhD, independent researcher and adjunct professor, University of South Carolina, Columbia, and consultant for Ortho-McNeil Janssen Scientific Affairs, L.L.C., the sponsor of the study.  "While the results will need further investigation to confirm these observations, a treatment that can potentially lead to reduced hospitalizations for schizophrenia may offer economic benefits to health-care systems that pay for schizophrenia-related inpatient care."

Study MethodsData for the analysis were from two phases of the clinical trial: a double-blind, randomized, relapse-prevention maintenance phase that compared INVEGA SUSTENNA to placebo and a one-year open-label extension of the study, during which all patients were treated with INVEGA SUSTENNA.

The change in schizophrenia-related hospitalization rates between the two phases of the study was evaluated for the group of patients treated with INVEGA SUSTENNA and for the group that received placebo. Data were obtained from an investigator-completed resource-use questionnaire. Overall change in hospitalization ra
'/>"/>

SOURCE Ortho-McNeil Janssen Scientific Affairs, L.L.C.
Copyright©2010 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6

Related medicine technology :

1. Trubion Announces Preliminary Analysis of Phase IIb Results With TRU-015 in Rheumatoid Arthritis
2. Oncology Drugs Development Update - Worldwide Markets and Forecasts of Approved EGFr/HEr2 Inhibitors, Treatment Costs, Pathway Analysis, Current and Expanded Clinical Indications, and Novel Agents in Development
3. New Data From Large Safety Analysis of MYCAMINE Shows Favorable Clinical Safety Profile
4. Immtech Announces Interim Analysis in Phase III African Sleeping Sickness Trial
5. Analysis Shows Vernakalant Hydrochloride Injection Increases Conversion to Normal Heart Rhythm in Acute Atrial Fibrillation Patients Treated Within 48 Hours of Onset
6. New Analysis of Study Data Shows That Asacol(R) (Mesalamine) Delivers Rapid Symptom Relief for Ulcerative Colitis Patients
7. A Sociolinguistic Analysis of In-Office Dialogue Reveals Psychiatrists and Parents Have Significantly Different Perceptions on ADHD and Psychiatric Comorbidities
8. Favrille Provides Update on Timing of Analysis from Pivotal Phase 3 Clinical Trial; Reports Third Quarter 2007 Financial Results
9. Results Of VYVANSE(TM) (lisdexamfetamine dimesylate) Effect Size Analysis Presented at Major Scientific Meeting
10. Progen Presents Additional Analysis of Data from PI-88 Phase 2 Liver Cancer Study at American Association for the Study of Liver Diseases
11. Retrospective Analysis Finds That Initiation of Insulin Glargine in Patients With Type 2 Diabetes was Associated With a Lower Incidence Rate of Myocardial Infarction as Compared With NPH Insulin
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/22/2013)... , May 22, 2013  For the 3% of ... sweating is often embarrassing, uncomfortable, anxiety-inducing and disabling.  While ... or treated for their symptoms, hyperhidrosis is a serious ... solution available called Precision TX™. Dr. ... Skin & Laser Center in New York ...
(Date:5/22/2013)... , May 22, 2013  Modern Medical announced ... (ODM).  Launched in November 2012 in a test ... program to stop the rising opioid abuse in ... customized program designed to protect employees, physicians and ... the necessary balance to provide pain relief for ...
(Date:5/22/2013)... STEPh, Inc., a full service medical communications ... web site ( http://www.stephreports.com ) dedicated to ... STEPh Reports STEPh Reports are comprehensive critical ... STEPh Report assesses the competitive landscape by individual drug ... and specific key issues.  STEPh Reports are written by ...
Breaking Medicine Technology:Is There Finally A Way To Stop Severe Excessive Sweating? 2Modern Medical Introduces Opioid Abuse Solution to the Workers' Compensation Industry 2Scientific and Technical Evaluation of Pharmaceuticals, Inc. [STEPh, Inc.], Launches New Competitive Intelligence Web Site 2
... 2007 - Arrowhead,Research Corporation (NASDAQ:ARWR) announced today ... the Proceedings of the National Academy of ... to use multiple,systemic dosing with Calando's lead ... proprietary technologies in targeted,polymeric delivery systems and ...
... dermal patch and a direct,current power source ... 20, 2007 /PRNewswire/ -- Dharma Therapeutics,Inc., ("Dharma") ... wholly owned subsidiary of Transcutaneous Technologies, Inc.,("TTI"), ... technology, which administers lidocaine and epinephrine,through the ...
Cached Medicine Technology:Arrowhead Subsidiary, Calando Pharmaceuticals Publishes Study on,Targeted, Systemic Delivery of siRNA 2Arrowhead Subsidiary, Calando Pharmaceuticals Publishes Study on,Targeted, Systemic Delivery of siRNA 3Dharma Therapeutics Shows IDDS Is Effective in Reducing Pain,Associated With Insertion of an Intravenous Catheter in Their Phase,2 Clinical Trial 2Dharma Therapeutics Shows IDDS Is Effective in Reducing Pain,Associated With Insertion of an Intravenous Catheter in Their Phase,2 Clinical Trial 3
(Date:5/22/2013)... RI (PRWEB) May 22, 2013 Hurricane ... weatherproofing your home. That’s why Amica Insurance ... coverages for the upcoming hurricane season. , “An important ... said Bryan Cook, a senior assistant vice president at ... needs is before the threat of a storm.” , ...
(Date:5/22/2013)... HR Strategies recently participated in the Gwinnett ... Fairgrounds, on Friday May 10, 2013. For never having ... raising over $6,300 for cancer research. , HR ... the first $3,000 for Bronze Level Sponsorship. HR Strategies ... to match the company’s contribution of $3,000; and after ...
(Date:5/22/2013)... (PRWEB) May 22, 2013 Homeopathic Vibes is ... cannot make it to the store during normal hours. On ... “The change is to accommodate some of our patients who ... the day time or on Saturdays,” says owner and homeopathic ... 10 a.m. to 6 p.m. Monday through Friday; weekends are ...
(Date:5/22/2013)... Fish oil supplements could help reduce the risk ... The supplements, also known as omega-3 fatty ... that,s linked to insulin sensitivity, Harvard researchers found. ... have also been linked to a lower risk ... found fish oil increased circulating adiponectin, whether similar ...
(Date:5/22/2013)... depression have on his young son or daughter? When fathers ... their children benefit, said a University of Illinois study. , ... to be able to attend to the child,s emotional state, ... notice whether he is getting frustrated or needs help. Depressed ... U of I professor of human development. , But if ...
Breaking Medicine News(10 mins):Health News:Reviewing Insurance Policies: a Key Part of Hurricane Preparations 2Health News:HR Strategies Raises Over $6,300 for Cancer Research via Relay For Life 2Health News:Homeopathic Vibes Now Open Late on Wednesdays 2Health News:Fish Oil Pills Might Cut Diabetes Risk, Researchers Say 2Health News:Good marriage can buffer effects of dad's depression on young children 2
... Recent study reports that women don’t have to worry about their ... fertility is higher only in their thirties. // Women don’t have ... be a constraint for conception of babies. Researchers have found from ... as man as increased considerably. The fertility rate of women in ...
... as formed a new cabinet committee to plan strategies to ... has said that though the United Kingdom //Government has taken ... flu spread but the committee feels still a lot has ... ,The committee feels that the Government should organize the food ...
... Motion has been developed by University of Toronto scientists with ... again. The device makes the muscles// work again by sending ... called functional electrical stimulation or FES, is unlike similar therapies ... is not dependent on the machine. ,Instead, the ...
... it takes to get pregnant or conceive the sex of the ... by Dutch reserachers. //The sample size was 5,283 women who gave ... ,Among the 498 women who took longer than 12 months ... whereas the proportion of male births among the 4,785 women with ...
... UK Parliamentarian Roger Williams has called for a ban ... the production of 6,000 types of medicines, food and ... the sweetener, which is used in cereal, chocolate and ... published reports that aspartame caused cancer in rats. Doses ...
... the Government in treating drug addicts is beginning to yield ... users seeking treatment in 2004. Heroin users accounted for 8,000 ... the number of people trying to get back to normal ... the figures, which also said that the percentage of heroin ...
Cached Medicine News:
Straight, with guard. Ideal for multi-directional manipulation....
Vaulted shank with guard....
Vaulted shank. For engaging the inferior haptic without touching the dome of the IOL....
... adjusted for perfect focus where it's needed ... This, along with Keeler's wide angle light ... the patient's pupil size, you will see ... Lithium-ion technology provides a longer life battery ...
Medicine Products: